ImmunoGen, Inc. Announces Conference Call to Discuss Clinical Data Reported at Recent Medical Meetings
WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 3, 2009--
Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted
anticancer products, today announced that the Company will hold a
conference call at 8:00 a.m. ET on Monday, December 14, 2009, to review
the clinical data reported on TAP compounds at the AACR-NCI-EORTC,
American Society of Hematology, and San Antonio Breast Cancer Symposium
medical meetings held in November/December 2009. This call will include
comments by ImmunoGen’s Chief Executive Officer, Daniel Junius, Chief
Medical Officer, James O’Leary, MD, and Chief Scientific Officer, John
To access the live call by phone, dial 913-312-1426. Passcode is
3466172. The call also may be accessed through the Investor
Information section of the Company’s website, www.immunogen.com.
Following the live webcast, a replay of the call will be available at
the same location through December 28, 2009.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its
expertise in cancer biology, monoclonal antibodies and the creation and
attachment of potent cancer-cell killing agents. The Company’s Targeted
Antibody Payload (TAP) technology uses antibodies to deliver one of
ImmunoGen’s proprietary cancer-cell killing agents specifically to
cancer targets. In addition to the Company’s product pipeline, compounds
utilizing the TAP technology are in clinical testing through ImmunoGen’s
collaborations with Genentech (a wholly-owned member of the Roche
Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced
compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being
conducted by Genentech and Roche. Other ImmunoGen collaborative partners
include Bayer HealthCare and Amgen. More information about ImmunoGen can
be found at www.immunogen.com.
Source: ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Director, Investor Relations
and Corporate Communications
Close window | Back to top